Bile Acids in Nonalcoholic Fatty Liver Disease: New Concepts and Therapeutic Advances

被引:21
|
作者
Cruz-Ramon, Vania [1 ]
Chinchilla-Lopez, Paulina [1 ]
Ramirez-Perez, Oscar [1 ]
Mendez-Sanchez, Nahum [1 ]
机构
[1] Med Sur Clin & Fdn, Liver Res Unit, Puente Piedra 150, Mexico City 14050, DF, Mexico
关键词
Bile acids; NAFLD; Metabolism; Metabolic syndrome; NUCLEAR RECEPTOR; STEATOHEPATITIS; IDENTIFICATION; EPIDEMIOLOGY; METABOLISM; ALPHA;
D O I
10.5604/01.3001.0010.5498
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
Nonalcoholic liver disease (NAFLD) is a major emerging health burden that is a common cause of illness and death worldwide. NAFLD can progress into nonalcoholic steatohepatitis (NASH) which is a severe form of liver disease characterized by inflammation and fibrosis. Further progression leads to cirrhosis, which predisposes patients to hepatocellular carcinoma or liver failure. The mechanism of the progression from simple steatosis to NASH is unclear. However, there are theories and hypothesis which support the link between disruption of the bile acids homeostasis and the progression of this disorder. Previous studies have been demonstrated that alterations of these pathways can lead to dysregulation of energy balance and an increase of liver inflammation and fibrosis. In this review, we summarized the current knowledge of the interaction between BA and the process related to the development of NAFLD, besides, the potential targets for novel therapies.
引用
收藏
页码:S58 / S67
页数:10
相关论文
共 50 条
  • [1] Bile Acid Receptors and the Gut-Liver Axis in Nonalcoholic Fatty Liver Disease
    Xue, Rui
    Su, Lianyong
    Lai, Shengyi
    Wang, Yanyan
    Zhao, Derrick
    Fan, Jiangao
    Chen, Weidong
    Hylemon, Phillip B.
    Zhou, Huiping
    CELLS, 2021, 10 (11)
  • [2] Bile Acids and Nonalcoholic Fatty Liver Disease: Molecular Insights and Therapeutic Perspectives
    Arab, Juan P.
    Karpen, Saul J.
    Dawson, Paul A.
    Arrese, Marco
    Trauner, Michael
    HEPATOLOGY, 2017, 65 (01) : 350 - 362
  • [3] The role of bile acids in nonalcoholic fatty liver disease and nonalcoholic steatohepatitis
    Chow, Monica D.
    Lee, Yi-Horng
    Guo, Grace L.
    MOLECULAR ASPECTS OF MEDICINE, 2017, 56 : 34 - 44
  • [4] Interaction of gut microbiota with dysregulation of bile acids in the pathogenesis of nonalcoholic fatty liver disease and potential therapeutic implications of probiotics
    Chen, Jiezhong
    Thomsen, Michael
    Vitetta, Luis
    JOURNAL OF CELLULAR BIOCHEMISTRY, 2019, 120 (03) : 2713 - 2720
  • [5] Exploring serum bile acids as potential noninvasive biomarkers for nonalcoholic fatty liver disease
    Basuni, Ashraf Abbass
    Sweed, Dina
    Elgazzar, Mohammed Fathey
    Khalil, Ashraf
    EGYPTIAN LIVER JOURNAL, 2024, 14 (01)
  • [6] Role of Bile Acids in Dysbiosis and Treatment of Nonalcoholic Fatty Liver Disease
    Wang, Caihua
    Zhu, Chunpeng
    Shao, Liming
    Ye, Jun
    Shen, Yimin
    Ren, Yuezhong
    MEDIATORS OF INFLAMMATION, 2019, 2019
  • [7] Advances in nonalcoholic fatty liver disease
    Moreno Sanchez, Diego
    MEDICINA CLINICA, 2009, 133 (07): : 258 - 260
  • [8] Bile acids and insulin resistance: implications for treating nonalcoholic fatty liver disease
    Wei, Jue
    Qiu, De Kai
    Ma, Xiong
    JOURNAL OF DIGESTIVE DISEASES, 2009, 10 (02) : 85 - 90
  • [9] Modulation of the gut microbiota impacts nonalcoholic fatty liver disease: a potential role for bile acids
    Janssen, Aafke W. F.
    Houben, Tom
    Katiraei, Saeed
    Dijk, Wieneke
    Boutens, Lily
    van der Bolt, Nieke
    Wang, Zeneng
    Brown, J. Mark
    Hazen, Stanley L.
    Mandard, Stephane
    Shiri-Sverdlov, Ronit
    Kuipers, Folkert
    van Dijk, Ko Willems
    Vervoort, Jacques
    Stienstra, Rinke
    Hooiveld, Guido J. E. J.
    Kersten, Sander
    JOURNAL OF LIPID RESEARCH, 2017, 58 (07) : 1399 - 1416
  • [10] Novel therapeutic targets for nonalcoholic fatty liver disease
    Eguchi, Akiko
    Povero, Davide
    Alkhouri, Naim
    Feldstein, Ariel E.
    EXPERT OPINION ON THERAPEUTIC TARGETS, 2013, 17 (07) : 773 - 779